Smart, D.
The Environmental Mutagenesis and Genomics Society
E-cigarettes are being developed as potentially reduced-risk alternatives to continued smoking. Among the different endpoints of toxicity under investigation, the induction of DNA damage by the chemical constituents present in the aerosols generated from e-cigarettes is an active field of research. The genotoxic potential of one principal aerosol component, nicotine, has been extensively studied for over four decades. However, characterization of its effects in modern-day in vitro genotoxicity methods is scarce. While e-liquids—the matrices aerosolized by e-cigarette devices—are a relatively recent innovation and, as such, have only been the subject of testing for less than ten years. E-liquids are highly diverse and can contain varying proportions of nicotine, flavoring agents, and humectants such as propylene glycol and vegetable glycerin. In our research, contemporary in vitro genetic toxicology approaches have been deployed to characterize the genotoxic potential of nicotine and e-liquids, with a particular focus on its biological relevance. Our results—generated from state-of-the-art regulatory tests, quantitative concentration–response analyses, mode-of-action assessments, and a novel integrated genotoxicity assay in human cells—reveal a likely minimal level of biological and physiological relevance for the effects observed. In addition, the findings of a literature survey unveil a number of opportunities for improving the study of e-cigarette-derived aerosols in submerged cell culture-based assays.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.